nadolol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 1865 42200-33-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nadolol
  • corgard
  • anabet
  • solgol
A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.
  • Molecular weight: 309.41
  • Formula: C17H27NO4
  • CLOGP: 0.38
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 81.95
  • ALOGS: -2.14
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.16 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.25 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 73 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 34.58 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.14 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.20 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.231 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.851 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.350 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.271 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 86.210 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 75.080 % High 1
herg hERG pIC50 4.202 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.309 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.105 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 91.170 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,IKBKB,ITK,JAK3,MAP2K6,MAP3K7,MAPK7,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,TEK,TGFBR1,ZAP70 31
kinase-selectivity-class CDK4 1
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.633 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.086 High 1
mh-clint Mouse hepatocyte intrinsic clearance 2.239 High 1
mppb Mouse plasma protein binding (% unbound) 90.060 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.982 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 92.140 % High 1
rat-kpuu-brain Rat brain Kpuu 0.007 % High 1
rh-clint Rat hepatocyte intrinsic clearance 0.908 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 89.700 % High 1
rppb Rat plasma protein binding (% unbound) 90.020 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 933.254 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 10, 1979 FDA KING PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 1331.41 17.67 418 15209 37552 90575268
Chronic sinusitis 559.30 17.67 194 15433 23608 90589212
Vaginal flatulence 462.31 17.67 144 15483 12494 90600326
Paraesthesia oral 445.17 17.67 177 15450 31482 90581338
Female genital tract fistula 440.48 17.67 151 15476 17717 90595103
Proctitis 435.62 17.67 144 15483 15115 90597705
Radiculopathy 427.58 17.67 149 15478 18356 90594464
Vaginal discharge 401.29 17.67 144 15483 19320 90593500
Procedural pain 375.28 17.67 159 15468 33201 90579619
Oral candidiasis 324.02 17.67 146 15481 35309 90577511
Rectal haemorrhage 306.82 17.67 186 15441 82558 90530262
Frequent bowel movements 277.66 17.67 153 15474 56782 90556038
Haematochezia 264.37 17.67 160 15467 70753 90542067
Colitis ulcerative 264.15 17.67 151 15476 60115 90552705
Weight decreased 253.57 17.67 319 15308 379591 90233229
Colitis 245.85 17.67 152 15475 69790 90543030
Dyspepsia 232.53 17.67 224 15403 197936 90414884
Therapeutic product effect incomplete 217.76 17.67 214 15413 193682 90419138
Drug ineffective 210.39 17.67 615 15012 1383683 89229137
Neovascularisation 209.42 17.67 50 15577 1580 90611240
Paradoxical drug reaction 146.96 17.67 50 15577 5716 90607104
Abdominal pain 145.24 17.67 251 15376 395470 90217350
Anaemia 116.77 17.67 214 15413 352588 90260232
Erythema 113.69 17.67 167 15460 229079 90383741
Constipation 109.52 17.67 183 15444 280212 90332608
Anuria 101.33 17.67 50 15577 14768 90598052
Extrapyramidal disorder 99.70 17.67 51 15576 16252 90596568
Infusion related reaction 73.01 17.67 196 15431 416584 90196236
Malaise 71.93 17.67 243 15384 585743 90027077
Drug ineffective for unapproved indication 66.28 17.67 69 15558 66575 90546245
Nausea 54.04 17.67 351 15276 1109965 89502855
Arthropathy 51.13 17.67 3 15624 366239 90246581
Systemic lupus erythematosus 47.52 17.67 4 15623 361892 90250928
Off label use 46.20 17.67 336 15291 1101916 89510904
Varices oesophageal 45.75 17.67 19 15608 3760 90609060
Synovitis 45.13 17.67 3 15624 329749 90283071
Pyrexia 44.57 17.67 228 15399 660257 89952563
Abdominal discomfort 40.24 17.67 16 15611 477312 90135508
Headache 37.21 17.67 265 15362 862481 89750339
Migraine 36.79 17.67 93 15534 190299 90422521
Contraindicated product administered 35.96 17.67 6 15621 320133 90292687
Hepatic enzyme increased 35.89 17.67 9 15618 360727 90252093
Hyperplastic cholecystopathy 31.61 17.67 7 15620 157 90612663
Joint swelling 30.79 17.67 25 15602 503275 90109545
Electrocardiogram QT prolonged 29.14 17.67 48 15579 72408 90540412
Alopecia 28.57 17.67 26 15601 495045 90117775
Hypersensitivity 28.55 17.67 22 15605 454655 90158165
Hepatic cirrhosis 28.31 17.67 44 15583 63209 90549611
Ligament sprain 28.22 17.67 22 15605 14577 90598243
General physical health deterioration 28.16 17.67 13 15614 355102 90257718
Ear congestion 27.73 17.67 13 15614 3429 90609391
Discomfort 26.98 17.67 7 15620 274328 90338492
Gastrointestinal disorder 26.32 17.67 6 15621 256681 90356139
Hypophosphataemia 25.76 17.67 21 15606 14833 90597987
Vomiting 25.43 17.67 62 15565 788231 89824589
Mobility decreased 25.43 17.67 6 15621 250728 90362092
Withdrawal syndrome 23.61 17.67 24 15603 22500 90590320
Stomatitis 23.47 17.67 9 15618 274689 90338131
Rash 23.10 17.67 66 15561 796034 89816786
Insulin-like growth factor increased 23.08 17.67 8 15619 966 90611854
Maternal exposure during pregnancy 21.86 17.67 18 15609 360045 90252775
Splenomegaly 21.84 17.67 18 15609 12906 90599914
Open reduction of fracture 21.70 17.67 8 15619 1154 90611666
Oligohydramnios 21.16 17.67 14 15613 7187 90605633
Impaired healing 21.15 17.67 7 15620 234192 90378628
Therapeutic product effect delayed 21.13 17.67 11 15616 3630 90609190
Pain 21.06 17.67 263 15364 996078 89616742
Blood cholesterol increased 21.05 17.67 5 15622 208007 90404813
Blister 20.73 17.67 9 15618 254989 90357831
Musculoskeletal stiffness 20.38 17.67 13 15614 296519 90316301
Electrocardiogram PR prolongation 20.05 17.67 7 15620 863 90611957
Hypertension 19.96 17.67 30 15597 457502 90155318
Rheumatoid factor positive 19.75 17.67 3 15624 171647 90441173
Ascites 19.70 17.67 32 15595 47708 90565112
Sleep disorder 19.57 17.67 5 15622 198025 90414795
Therapeutic product effect decreased 19.30 17.67 12 15615 277559 90335261
Irritable bowel syndrome 19.09 17.67 6 15621 207442 90405378
Intraventricular haemorrhage neonatal 18.41 17.67 5 15622 266 90612554
Hepatic cancer 18.12 17.67 11 15616 4870 90607950
Aortic arteriosclerosis 18.02 17.67 13 15614 7671 90605149
Swelling 17.78 17.67 28 15599 419030 90193790

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic encephalopathy 98.25 16.90 45 5025 16397 42599868
Varices oesophageal 88.26 16.90 29 5041 4336 42611929
Hepatic cirrhosis 54.08 16.90 32 5038 19670 42596595
Ascites 51.17 16.90 47 5023 56631 42559634
Hepatic failure 45.33 16.90 37 5033 38063 42578202
Oesophageal varices haemorrhage 38.76 16.90 15 5055 3592 42612673
Portal hypertensive gastropathy 36.37 16.90 10 5060 813 42615452
Hypoglycaemia 36.27 16.90 40 5030 59814 42556451
Bradycardia 32.22 16.90 45 5025 85439 42530826
Lactic acidosis 28.72 16.90 31 5039 45230 42571035
Ammonia increased 28.59 16.90 13 5057 4646 42611619
Chronic hepatic failure 24.54 16.90 7 5063 651 42615614
Sinus arrest 23.29 16.90 9 5061 2147 42614118
Acute kidney injury 22.74 16.90 95 4975 367242 42249023
Liver transplant 18.07 16.90 8 5062 2683 42613582
Haemoglobin decreased 17.02 16.90 44 5026 132427 42483838

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic sinusitis 544.17 16.41 191 18233 24893 110545982
Macular degeneration 485.44 16.41 169 18255 21490 110549385
Vaginal flatulence 468.48 16.41 143 18281 12001 110558874
Female genital tract fistula 453.09 16.41 150 18274 16369 110554506
Paraesthesia oral 433.45 16.41 175 18249 33496 110537379
Radiculopathy 426.09 16.41 149 18275 19187 110551688
Proctitis 421.79 16.41 143 18281 16784 110554091
Vaginal discharge 413.89 16.41 143 18281 17765 110553110
Procedural pain 367.33 16.41 158 18266 35407 110535468
Oral candidiasis 296.25 16.41 146 18278 44614 110526261
Rectal haemorrhage 263.38 16.41 192 18232 119641 110451234
Frequent bowel movements 250.27 16.41 153 18271 71237 110499638
Dyspepsia 247.97 16.41 225 18199 190740 110380135
Colitis ulcerative 243.94 16.41 155 18269 77208 110493667
Weight decreased 221.44 16.41 327 18097 467730 110103145
Haematochezia 213.68 16.41 167 18257 115357 110455518
Neovascularisation 207.96 16.41 50 18374 1687 110569188
Therapeutic product effect incomplete 201.60 16.41 216 18208 223589 110347286
Colitis 198.11 16.41 152 18272 102171 110468704
Abdominal pain 125.83 16.41 269 18155 512720 110058155
Paradoxical drug reaction 122.70 16.41 50 18374 9767 110561108
Varices oesophageal 108.50 16.41 42 18382 7173 110563702
Anaemia 99.23 16.41 255 18169 546831 110024044
Erythema 90.73 16.41 169 18255 291278 110279597
Infusion related reaction 90.02 16.41 197 18227 380965 110189910
Constipation 82.30 16.41 183 18241 357603 110213272
Anuria 82.24 16.41 51 18373 24290 110546585
Hepatic encephalopathy 77.68 16.41 52 18372 28204 110542671
Extrapyramidal disorder 71.94 16.41 50 18374 28817 110542058
Hepatic cirrhosis 63.80 16.41 67 18357 67559 110503316
Malaise 60.14 16.41 246 18178 671573 109899302
Ascites 57.42 16.41 74 18350 92734 110478141
Headache 53.91 16.41 289 18135 882088 109688787
Nausea 50.59 16.41 365 18059 1235325 109335550
Migraine 47.77 16.41 95 18329 171557 110399318
Oesophageal varices haemorrhage 44.62 16.41 20 18404 4925 110565950
Drug ineffective for unapproved indication 41.57 16.41 67 18357 102771 110468104
Drug ineffective 38.05 16.41 403 18021 1520137 109050738
Portal hypertensive gastropathy 35.57 16.41 13 18411 1895 110568980
Ammonia increased 34.94 16.41 20 18404 8230 110562645
Hypoglycaemia 34.41 16.41 66 18358 116038 110454837
Pyrexia 34.16 16.41 261 18163 898004 109672871
Arthropathy 34.02 16.41 4 18420 287518 110283357
Open reduction of fracture 33.04 16.41 8 18416 278 110570597
Hepatic failure 32.28 16.41 48 18376 68691 110502184
Pain 30.65 16.41 267 18157 954688 109616187
Hepatic enzyme increased 30.32 16.41 8 18416 320884 110249991
Hyperplastic cholecystopathy 29.40 16.41 7 18417 226 110570649
Ligament sprain 29.16 16.41 23 18401 16045 110554830
Systemic lupus erythematosus 28.97 16.41 4 18420 254334 110316541
Wound 28.39 16.41 3 18421 234434 110336441
Off label use 28.35 16.41 377 18047 1499808 109071067
Splenomegaly 28.11 16.41 27 18397 24471 110546404
Torsade de pointes 28.02 16.41 26 18398 22574 110548301
Ear congestion 27.37 16.41 13 18411 3652 110567223
Inability to afford medication 26.06 16.41 13 18411 4063 110566812
Gastrointestinal disorder 24.91 16.41 5 18419 241947 110328928
Hepatic cancer 24.74 16.41 18 18406 11138 110559737
Abdominal discomfort 24.40 16.41 18 18406 393840 110177035
Contraindicated product administered 23.81 16.41 6 18418 248261 110322614
Stomatitis 23.24 16.41 8 18416 270234 110300641
Portal vein thrombosis 21.86 16.41 14 18410 7044 110563831
Bradycardia 21.67 16.41 66 18358 155451 110415424
Febrile neutropenia 21.60 16.41 13 18411 316754 110254121
Neutropenia 20.87 16.41 19 18405 374601 110196274
Oligohydramnios 20.53 16.41 11 18413 3983 110566892
Electrocardiogram QT prolonged 19.87 16.41 51 18373 108909 110461966
Musculoskeletal stiffness 19.77 16.41 11 18413 279811 110291064
Joint swelling 19.70 16.41 27 18397 442818 110128057
Hypersensitivity 19.66 16.41 23 18401 403975 110166900
Lactic acidosis 19.64 16.41 46 18378 92765 110478110
Therapeutic product effect delayed 19.35 16.41 11 18413 4468 110566407
Intramedullary rod insertion 19.18 16.41 5 18419 235 110570640
Mobility decreased 18.80 16.41 8 18416 237414 110333461
Electrocardiogram PR prolongation 18.39 16.41 8 18416 1835 110569040
Hypoglycaemic unconsciousness 17.98 16.41 7 18417 1213 110569662
C-reactive protein increased 17.81 16.41 7 18417 217912 110352963
Vomiting 17.59 16.41 85 18339 910590 109660285
Gastrointestinal haemorrhage 17.50 16.41 64 18360 165454 110405421
Discomfort 17.37 16.41 7 18417 214700 110356175
Sinus arrest 17.21 16.41 10 18414 4232 110566643
Sleep disorder 16.87 16.41 6 18418 198638 110372237
Insulin-like growth factor increased 16.71 16.41 8 18416 2288 110568587
Maternal exposure during pregnancy 16.63 16.41 11 18413 254872 110316003
Gastric varices 16.43 16.41 6 18418 873 110570002

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C07AA12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, non-selective
ATC C07BA12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND THIAZIDES
Beta blocking agents, non-selective, and thiazides
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D013565 Sympatholytics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
CHEBI has role CHEBI:35530 ฮฒ-adrenergic antagonist
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66991 sympatholytic agent

Related Drugs by ATC class:

C07AA Beta blocking agents, non-selective 13 drugs
alprenololbopindololbupranololcarteololcloranololmepindololoxprenololpenbutololpindololpropranololsotaloltertatolol show all 13 →
C07BA Beta blocking agents, non-selective, and thiazides 5 drugs
metipranololoxprenololpropranololsotaloltimolol

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Angina pectoris indication 194828000
Thyrotoxicosis off-label use 90739004 DOID:7997
Mitral valve prolapse off-label use 409712001
Essential tremor off-label use 609558009 DOID:4990
Prevention of Congenital Long QT Syndrome associated Ventricular Arrhythmia off-label use
Myocardial Reinfarction Prevention off-label use
Prevention of Bleeding Esophageal Varices off-label use
Migraine Prevention off-label use
Anuria contraindication 2472002 DOID:2983
Bronchospasm contraindication 4386001
Hypercholesterolemia contraindication 13644009
Complete atrioventricular block contraindication 27885002
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Anaphylaxis contraindication 39579001
Hypokalemia contraindication 43339004
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Hypomagnesemia contraindication 190855004
Partial atrioventricular block contraindication 195039008
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Right ventricular failure contraindication 367363000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.57 acidic
pKa2 9.31 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 6.90 IUPHAR CHEMBL
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 8.60 IUPHAR CHEMBL
Beta-3 adrenergic receptor GPCR ANTAGONIST Ki 6.30 IUPHAR

External reference:

IDSource
4017603 VUID
N0000145983 NUI
D00432 KEGG_DRUG
4017603 VANDF
C0027302 UMLSCUI
CHEBI:7444 CHEBI
CHEMBL521606 ChEMBL_ID
DB01203 DRUGBANK_ID
D009248 MESH_DESCRIPTOR_UI
39147 PUBCHEM_CID
554 IUPHAR_LIGAND_ID
3875 INN_ID
FEN504330V UNII
151549 RXNORM
2018 MMSL
31 MMSL
5143 MMSL
d00018 MMSL
001854 NDDF
387482003 SNOMEDCT_US
82896009 SNOMEDCT_US
220045-89-6 SECONDARY_CAS_RN
FEN504330V INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nadolol and Bendroflumethiazide HUMAN PRESCRIPTION DRUG LABEL 2 0115-5311 TABLET 40 mg ORAL ANDA 25 sections
Nadolol and Bendroflumethiazide HUMAN PRESCRIPTION DRUG LABEL 2 0115-5322 TABLET 80 mg ORAL ANDA 25 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-686 TABLET 20 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-687 TABLET 40 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-688 TABLET 80 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 21695-799 TABLET 40 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 21695-800 TABLET 80 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 21695-802 TABLET 20 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 42254-094 TABLET 20 mg ORAL ANDA 15 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 42254-218 TABLET 40 mg ORAL ANDA 15 sections
NADOLOL Human Prescription Drug Label 1 46708-402 TABLET 20 mg ORAL ANDA 17 sections
NADOLOL Human Prescription Drug Label 1 46708-403 TABLET 40 mg ORAL ANDA 17 sections
NADOLOL Human Prescription Drug Label 1 46708-404 TABLET 80 mg ORAL ANDA 17 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 50090-7995 TABLET 20 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 51407-977 TABLET 20 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 51407-978 TABLET 40 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 51407-979 TABLET 80 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 54868-3257 TABLET 40 mg ORAL ANDA 12 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 54868-3721 TABLET 80 mg ORAL ANDA 12 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 54868-5295 TABLET 20 mg ORAL ANDA 12 sections
Nadolol Human Prescription Drug Label 1 59651-251 TABLET 40 mg ORAL ANDA 19 sections
Nadolol Human Prescription Drug Label 1 59651-252 TABLET 80 mg ORAL ANDA 19 sections
Nadolol Human Prescription Drug Label 1 59651-589 TABLET 20 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 60687-302 TABLET 20 mg ORAL ANDA 18 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 60687-313 TABLET 40 mg ORAL ANDA 18 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 60687-887 TABLET 20 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 60687-887 TABLET 20 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 60687-898 TABLET 40 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 60687-898 TABLET 40 mg ORAL ANDA 20 sections
NADOLOL Human Prescription Drug Label 1 62332-402 TABLET 20 mg ORAL ANDA 17 sections